Characterizing Real-World Use Of Tiotropium In Asthma In The USA.
Carlyne M AverellFrançois LalibertéMei Sheng DuhJennifer W WuGuillaume GermainSarai FaisonPublished in: Journal of asthma and allergy (2019)
This study provided insights into real-world US use of TIO in asthma. Overall, 16-19% of patients received TIO monotherapy and had high baseline exacerbation rates, suggesting that additional ICS-containing medication may be beneficial. Patients initiating triple therapy were among the most severe, with high baseline exacerbation rates and rescue medication use, and had high post-treatment ICS discontinuation rates, suggesting unmet needs in this population.
Keyphrases
- chronic obstructive pulmonary disease
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- intensive care unit
- combination therapy
- early onset
- acute respiratory distress syndrome
- patient reported
- open label
- allergic rhinitis
- cell therapy